709652-82-4

Basic information

• Product Name: 2-AMINO-5-BROMO-NICOTINONITRILE
• Synonyms: 2-AMINO-5-BROMO-NICOTINONITRILE;2-Amino-5-bromo-3-pyridinecarbonitrile;2-Amino-5-bromo-nicotinonitrile ,97%;2-AMino-5-broMo-3-cyanopyridine
• CAS NO: 709652-82-4
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02006
• Mol File: 709652-82-4.mol

Chemical Properties

• Boiling Point: 286.1 °C at 760 mmHg
• Flash Point: 126.8 °C
• Appearance: /
• Density: 1.8 g/cm³
• Vapor Pressure: 0.00269mmHg at 25°C
• Refractive Index: 1.66
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 0.84±0.49(Predicted)
• CAS DataBase Reference: 2-AMINO-5-BROMO-NICOTINONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-BROMO-NICOTINONITRILE(709652-82-4)
• EPA Substance Registry System: 2-AMINO-5-BROMO-NICOTINONITRILE(709652-82-4)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25-37/38-41-20/21/22
• Safety Statements: 26-36-45-36/37-24/25
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 709652-82-4(Hazardous Substances Data)

Usage

Chemical Properties

Light brown solid

InChI:InChI=1/C6H4BrN3/c7-5-1-4(2-8)6(9)10-3-5/h1,3H,(H2,9,10)

Upstream product

• 24517-64-4 2-amino-3-pyridinecarbonitrile 
• 1350452-24-2 2-amino-6-(methylthio)-4-(trimethylsilyl)nicotinonitrile 
• 114078-88-5 5-bromo-1,2,3-triazine 
• 109-77-3 malononitrile 
• 1093963-85-9 2-amino-6-(methylthio)nicotinonitrile 
• 1508-07-2 1,1-dicyanopropene 
• 1350452-23-1 2-(1-(trimethylsilyl)ethylidene)malononitrile 

Downstream Products

• 941604-21-3 N-(5-bromo-3-cyano-pyridin-2-yl)-acetamide 
• 405224-23-9 5-bromo-2-chloropyridine-3-carbonitrile 
• 1246362-01-5 tert-butyl (2R)-1-(4-(6-amino-5-cyanopyridin-3-yl)phenyl)-4-(3-(7-fluoro-1-(3-methoxypropyl)-3-methyl-1H-indol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate 
• 1267853-94-0 2-amino-5-(4-aminophenyl)nicotinonitrile 
• 1267849-53-5 1-[4-(6-amino-5-cyanopyridin-3-yl)-phenyl]-3-(5-tert-butylisoxazol-3-yl)urea 
• 1428799-42-1 C₂₀H₂₄BrN₅O 
• 1428799-37-4 5-bromo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine-3-amine 
• 1428799-38-5 C₂₈H₂₈N₆O₂ 
• 1426221-36-4 ethyl 7-(6-amino-5-cyanopyridin-3-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1246372-66-6 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile 
• 1335057-71-0 3-(aminomethyl)-5-bromopyridin-2-amine 
• 1443677-11-9 6-bromo-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one 
• 1121633-45-1 6-bromopyrido[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

Efficient and library-friendly synthesis of 4-N-substituted 6-bromopyrido[2,3-d]pyrimidines under microwave irradiation

In this paper, a novel synthetic method for 4-N-substituted 6-bromopyrido[2,3-d]pyrimidines was reported. Starting from 2-aminonicotinonitrile, following by bromination of aromatic ring, condensation, cyclization, and Dimroth rearrangement, a series of 21 new pyrido[2,3-d]pyrimidine derivatives was prepared in high yields (up to 98%). In the last two steps, microwave irradiation was used. The structures of synthesized compounds were determined by NMR, IR, and HRMS techniques. The results showed that application of microwave irradiation has a beneficial effect for the preparation of desired products, as it is simple and efficient method for improving the yields and reducing the formation of undesirable by-products.

Access to pyridines via cascade nucleophilic addition reaction of 1,2,3-triazines with activated ketones or acetonitriles

We studied the cascade nucleophilic addition reactions of 1,2,3-triazines with activated acetonitriles or ketones, which were used to construct highly substituted pyridines that are not easily accessed by conventional methods. The strategy addressed some structural diversity issues currently facing medicinal chemistry, and the resulting pyridines could be used as convenient precursors for the synthesis of related pharmaceuticals. In particular, our method was applied to the syntheses of the marketed drug etoricoxib and several biologically important molecules in a few steps.

Synthesis method and applications of polysubstituted 2-aminopyridine derivative

The invention belongs to the field of organic synthetic chemistry, and relates to a synthetic method and applications of a polysubstituted 2-aminopyridine derivative. According to the method, a 1,2,3-triazine compound and a cyanomethyl compound are used as substrates and are subjected to a one-step cycloaddition reaction under an alkaline condition to obtain a polysubstituted 2-aminopyridine derivative, wherein the reaction does not involve in danger and control reagents and medicines, and a simple, safe, efficient and environment-friendly strategy is provided for synthesizing the polysubstituted 2-aminopyridine derivative. According to the present invention, the obtained product is subjected to further derivatization, such that the active molecule or the drug molecule containing the 2-aminopyridine structure can be synthesized, such as active molecule SC-53606, drug molecule apatinib and nevirapine.

COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

INHIBITORS OF HEMEPROTEIN-CATALYZED LIPID PEROXIDATION

Compounds, compositions and methods related to the prevention or treatment of isoprostane-mediated tissue damage in a mammalian subject in need thereof.

OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES

Compounds of the formula I in which R1-R3 and Z have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridine derivatives as potent c-met inhibitors

A series of imidazo[1,2-a]pyridine derivatives against c-Met was designed by means of bioisosteric replacement. In this study, a selective, potent c-Met inhibitor, 22e was identified, with IC50 values of 3.9 nM against c-Met kinase and 45.0 nM

IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF

The invention provides compounds of formula (1), stereoisomers and tautomers thereof, or pharmaceutically acceptable salts, solvates and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by one or more proinflammatory cytokines selected from TNF-a, IL-Ιβ, IL-6, IL-8, IL-12, IL-17 or IL-23.

QUINOLONE COMPOUND

The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optional

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.